Promoter holding
64.27%
NP
Nivedita Pharma Private Limited - Due diligence report
A 360° intelligence report on Nivedita Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Nivedita Pharma Private Limited — 360° Intelligence Report
Generated from MCA filings & public records82/100
Trust Score
Low Risk
Nivedita Pharma Private Limited is assessed as Low Risk with a Trust Score of 82/100. Nivedita Pharma Private Limited is an active private limited indian non-government company incorporated in 2011, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.
Report generated on 29 Jul 2026 from the latest processed filings. Nivedita Pharma Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
82/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
45/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
25/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 25/100 Caution Indicated
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Elevated gearing (D/E 1.42).
- Working-capital cover adequate.
Charges position: 26 open (83.30 cr) · 0 satisfied (-).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 26 | 48.0 cr |
Compliance Score: 100/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| RITU AGARWAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANUJ GOYAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 2 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
06
Ownership & Group Intelligence
As per FY 2022 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 0 transfer(s)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 65 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +2.1x over 4 year(s).
Asset base grew 24% - capacity expansion.
Operating for 14+ years.
Distress signals & risk flags
26 open charge(s) registered - assets are encumbered.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence92/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment50/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 26 open charge(s) of 83.30 cr already registered.
- Compliance record supports lending.
Investor view62/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events27 Nov 2025
Charge created
Others - 2.25 cr
08 Nov 2025
Charge created
Others - 4.30 cr
27 Sep 2025
Last AGM held
Annual general meeting
10 Sep 2025
Charge created
Others - 3.80 cr
05 Jul 2025
Charge created
Others - 3.50 cr
05 May 2025
Charge created
Others - 4.50 cr
31 Mar 2025
Latest balance sheet
Filed with ROC
06 Mar 2025
Charge created
Others - 4.00 cr
07 Jan 2025
Charge created
Others - 4.05 cr
13 Nov 2024
Charge created
Others - 3.90 cr
12 Sep 2024
Charge created
Others - 4.05 cr
05 Jul 2024
Charge created
Others - 3.50 cr
15 May 2024
Charge created
Others - 3.50 cr
20 Feb 2024
Charge created
Others - 80.00 Lakh
06 Jan 2024
Charge created
Others - 3.50 cr
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Sedulous Life Solutions Private Limited | U85100UR2021PTC012668 | Rishkesh, Uttarakhand, India |
| Bruit Medimpex Private Limited | U51909DL2010PTC205061 | Kashmere Gate, Delhi, India |
| Balaji Stock Consultants Private Limited | U67190WB2008PTC124622 | Kolkata, West Bengal, India |
| The Mobilestore | U51900MH2006PLC160647 | Thane, Maharashtra, India |
| V S S Creations Private Limited | U51909WB2013PTC190291 | Kolkata, West Bengal, India |
| Sodicate (India) Pvt Ltd | U74899DL1975PTC007665 | New Delhi, Delhi, India |
| Wondar Sewing Machines Private Limited | U29190MP2019PTC050319 | Indore, Madhya Pradesh, India |
| Mcg Associates Private Limited | U51432GA1995PTC001977 | Goa, Goa, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Nivedita Pharma Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Nivedita Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 25/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 65/100, margin trends, ownership structure and peer set for Nivedita Pharma Private Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 82/100, distress signals and MSME payment-delay disclosures - know whether Nivedita Pharma Private Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Nivedita Pharma Private Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Nivedita Pharma Private Limited an active company?
Nivedita Pharma Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).
Is Nivedita Pharma Private Limited financially healthy?
Nivedita Pharma Private Limited has a Financial Health Score of 45/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Nivedita Pharma Private Limited?
Its overall Trust Score is 82/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Nivedita Pharma Private Limited?
See the directors and ownership sections above for board and shareholding detail. 2 active director(s) are on record.
Does Nivedita Pharma Private Limited have loans or charges against its assets?
26 open charge(s) are registered against its assets.
Is Nivedita Pharma Private Limited up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).
Is it risky to lend to Nivedita Pharma Private Limited?
Its Credit Risk Score is 25/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
